Document Detail

Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in patients without gastrointestinal bleeding.
MedLine Citation:
PMID:  21098755     Owner:  NLM     Status:  In-Process    
OBJECTIVE: To review relevant studies for both primary and secondary antibiotic prophylaxis of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis without gastrointestinal bleeding.
DATA SOURCES: A search of PubMed (1980-July 2010) was conducted using the terms prophylaxis, SBP, and antibiotics. A manual review of bibliographies was conducted for inclusion of relevant articles.
STUDY SELECTION AND DATA EXTRACTION: Prospective studies and meta-analyses published in English were included.
DATA SYNTHESIS: Ten trials and 3 meta-analyses were included. Of the 10 trials, 2 examined the use of secondary prophylaxis for prevention of subsequent episodes of SBP, 4 examined the use of primary prophylaxis to prevent an initial SBP episode, and 4 examined the use of antibiotic prophylaxis in a mixed population. Seven trials evaluated the use of an antibiotic compared to placebo or no treatment. Only 1 trial evaluated norfloxacin versus trimethoprim/sulfamethoxazole. Trial duration varied from 24 days to 12 months. In general, trials examining norfloxacin as secondary prophylaxis found significantly decreased occurrence of SBP but no significant difference in mortality rates. Primary prophylaxis studies found no significant difference in the incidence of infections, including SBP, with norfloxacin or ciprofloxacin treatment but significantly lower incidence of gram-negative infections. Mixed population studies found a significantly decreased incidence of SBP but no significant difference in mortality. In the 3 meta-analyses, a significant decrease in mortality and an overall decrease in SBP incidence in the treatment groups were noted.
CONCLUSIONS: Based on currently available data, the use of prophylactic antibiotic therapy is warranted for the prevention of recurrent SBP in patients with cirrhosis and ascites. In patients with low ascetic fluid protein and at least 1 more risk factor, primary prophylaxis may be considered. Further studies with improved methodology are needed to determine whether prophylactic antibiotic therapy has an impact on mortality.
Marisel Segarra-Newnham; Amy Henneman
Related Documents :
23636735 - Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in...
10731015 - Field evaluation of the computer science and applications, inc. physical activity monitor.
24007625 - Yield of intermittent versus continuous eeg in comatose survivors of cardiac arrest tre...
24688075 - Measles antibody responses in children randomized to edmonston-zagreb measles vaccinati...
11442955 - Antibiotic prophylaxis for endocarditis prevention during transesophageal echocardiogra...
9875935 - The harris design-2 total hip replacement fixed with so-called second-generation cement...
Publication Detail:
Type:  Journal Article     Date:  2010-11-23
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1946-54     Citation Subset:  IM    
Veterans Affairs Medical Center, West Palm Beach, FL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacologic management of heart failure with preserved ejection fraction.
Next Document:  Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.